Sunvalley Communication

Sunvalley Communication At Sunvalley Communication we're driven by our expertise in translating clinical data and complex scientific knowledge into motivating communication materials, communication services, and continuing medical education programs.

Communication and Publishing

Operating as usual

The Onco'Zine Newsletter: 5 Things you May have Missed Last Month.  Click to read: https://conta.cc/3h76gBwClick on the ...
09/09/2020

The Onco'Zine Newsletter: 5 Things you May have Missed Last Month. Click to read: https://conta.cc/3h76gBw

Click on the link below to sign up to receive our newsletter (Onco'Zine and ADC Review | Journal of Antibody-drug Conjugates):

https://conta.cc/32c3yq8

With 9 FDA-approved and commercially available ADCs, and many more in clinical development, It's important to stay up to...
09/07/2020

With 9 FDA-approved and commercially available ADCs, and many more in clinical development, It's important to stay up to date with news about Antibody-drug Conjugates. Sign up for the ADC Review newsletter: https://conta.cc/3gMvdT4

Stay up-to-date with R&D and regulatory updates of Antibody-drug Conjugates (ADC) in HemOnc. Click on the link to sign u...
08/07/2020

Stay up-to-date with R&D and regulatory updates of Antibody-drug Conjugates (ADC) in HemOnc. Click on the link to sign up for our Newsletter!

https://adc.expert/newsletterandwebinars

@ASCO @AACR @CPhIww #oncoogy #hematology @myESMO @AAPSonline @AAPSComms #pharma @world_ADC

"...Having ever been diagnosed with periodontal disease puts a person at risk of colorectal cancer precursor lesions, so...
07/29/2020
Periodontal Disease Linked to the Development of Colorectal Cancer - Onco'Zine

"...Having ever been diagnosed with periodontal disease puts a person at risk of colorectal cancer precursor lesions, some of which may eventually lead to colorectal cancer..."

The prevalence of periodontitis is positively associated with the development of various forms of cancer, including colorectal cancer.

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to brexucabtagene autoleucel, formerly know...
07/25/2020
Onco'Zine - The International Oncology Network posted on LinkedIn

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to brexucabtagene autoleucel, formerly known as KTE-X19 (Tecartus™; Kite Pharma, a Gilead Company).

https://lnkd.in/gJx4bYc

#cartcell #cancertreatment #cancer #hematology Kite Pharma Gilead Sciences #hematology #lymphoma #NHL #fdaapproval

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to brexucabtagene autoleucel, formerly known as KTE-X19 (Tecartus™; Kite Pharma...

Linda Barnes and Ali Siahpush Join ImmuID’s Executive Board to help America get Back to Work
06/26/2020
Linda Barnes and Ali Siahpush Join ImmuID’s Executive Board to help America get Back to Work

Linda Barnes and Ali Siahpush Join ImmuID’s Executive Board to help America get Back to Work

REDMOND, Wash. (PRWEB) June 24, 2020 -- ImmuID, an alliance of three Washington (State) based companies (Pharmefex, Sync.MD, X-CELLSYSTEM), has appointed Linda S. Barnes, founder and Chief Executive Officer of X-CELLSYTEM, and Ali R. Siahpush, Ph.D., President and Founder of Pharmefex, as members of...

ImmuID,  an alliance of three Washington-based companies (Pharmefex, Sync.MD, and  X-CELLSYSTEM) has designed an integra...
06/24/2020
Linda Barnes and Ali Siahpush Join ImmuID’s Executive Board to help America get Back to Work

ImmuID, an alliance of three Washington-based companies (Pharmefex, Sync.MD, and X-CELLSYSTEM) has designed an integrated and comprehensive end-to-end system to manage the massive task of getting Americans safely and responsibly back to work following the COVID-19 pandemic.

As part of a systematic risk-based approach, ImmuID accelerates the speed at which large numbers of employees can be tested. This unique approach includes a daily symptom tracker, as well as a convenient platform for testing employees, and is especially designed to avoid a resurgence of COVID-19 cases until a vaccine against the SARS-CoV-2, the virus that causes COVID-19, may be available to protect employees.

Today, the alliance confirmed that it had appointed Linda S. Barnes and Ali R. Siahpush, Ph.D. as members of its executive board. To read the announcement: https://www.prweb.com/…/linda_barnes_and_…/prweb17214320.htm#!

For more information about ImmuID: https://www.immuid.com/

#covid19 #covid19 #sars #backtowork #virus #testing #Washington #sympton #employees #resurgence #protection #masks #pandamic #coronavirus

REDMOND, Wash. (PRWEB) June 24, 2020 -- ImmuID, an alliance of three Washington (State) based companies (Pharmefex, Sync.MD, X-CELLSYSTEM), has appointed Linda S. Barnes, founder and Chief Executive Officer of X-CELLSYTEM, and Ali R. Siahpush, Ph.D., President and Founder of Pharmefex, as members of...

ADC Review / Journal of Antibody-drug Conjugates
04/25/2020
ADC Review / Journal of Antibody-drug Conjugates

ADC Review / Journal of Antibody-drug Conjugates

Netherlands-based Synthon Biopharmaceuticals, a biopharmaceutical research, and development company creating innovative precision medicines including the anti-HER2 investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine, previously known as SYD985 for the treatment breast cancer, has been relaunched as Byondis.

04/10/2020
The Vector Lab

The Vector Lab

100 Editable Designs + 75 Fonts. Optimized for t-shirt designs, hats, patches, logos, product packaging, embroideries, or anything else that needs a graphic.

04/10/2020
Domestika

Domestika

Learn the basic principles of logo design as you find your personal identity as a designer. 50% OFF. Until 04/14.

Click to learn more.

A study published in the Journal of the American Medical Association (JAMA), demonstrates that abbreviated breast magnet...
02/26/2020
Building Evidence for Abbreviated MRI in Women with Dense Breasts - Onco'Zine

A study published in the Journal of the American Medical Association (JAMA), demonstrates that abbreviated breast magnetic resonance imaging (MRI) detected significantly more cancers than digital breast tomosynthesis (3-D mammography), in average-risk women with dense breast tissue.

https://www.oncozine.com/building-evidence-for-abbreviated-mri-in-women-with-dense-breasts/

#breastcancerresearch #breastcancerawareness #cancerresearch #densetissue #MRI #mammography #mammogram #jama #cancerrisk #breaskcancerrisk

A study published in the Journal of the American Medical Association (JAMA), demonstrates that abbreviated breast magnetic resonance imaging (MRI) detected significantly more cancers than digital breast tomosynthesis (3-D mammography), in average-risk women with dense breast tissue. Breast tomosynth...

A long-term health study exploring the links between lifestyle, diet shows that the intake of dairy milk is associated w...
02/26/2020
Drinking Milk May Increase Rate of Breast Cancer by up to 50% - Onco'Zine

A long-term health study exploring the links between lifestyle, diet shows that the intake of dairy milk is associated with a greater risk of breast cancer in women.

https://www.oncozine.com/drinking-milk-may-increase-rate-of-breast-cancer-by-up-to-50/

#milk #dairy #cancer #breastcancer #cancerresearch #cancertreatment #clinicalstudy #drinkingmilk #cancerrisk #women #womenhealth

The Adventist Health Study-2 among members of the Seventh-day Adventist Chutch shows that intake of milk is associated with a greater risk of breast cancer.

A long-term health study exploring the links between lifestyle, diet shows that the intake of dairy milk is associated w...
02/26/2020
Drinking Milk May Increase Rate of Breast Cancer by up to 50% - Onco'Zine

A long-term health study exploring the links between lifestyle, diet shows that the intake of dairy milk is associated with a greater risk of breast cancer in women.

https://www.oncozine.com/drinking-milk-may-increase-rate-of-breast-cancer-by-up-to-50/

#milk #dairy #cancer #breastcancer #cancerresearch #cancertreatment #clinicalstudy #drinkingmilk #cancerrisk #women #womenhealth

The Adventist Health Study-2 among members of the Seventh-day Adventist Chutch shows that intake of milk is associated with a greater risk of breast cancer.

Karius Secures US $165 M Series B Funding; Expands Access to its Microbial cell-free DNA technology - Onco'Zine
02/24/2020
Karius Secures US $165 M Series B Funding; Expands Access to its Microbial cell-free DNA technology - Onco'Zine

Karius Secures US $165 M Series B Funding; Expands Access to its Microbial cell-free DNA technology - Onco'Zine

Karius, the world leader in non-invasive liquid biopsy for infectious diseases designed helps clinicians make rapid treatment decisions, secured US $ 165 million in new (Series B) funding. The funding round was led by SoftBank Vision Fund 2, with additional participation from General Catalyst, HBM H...

In an OpEd in Onco'Zine, Shannon Sovndal, MD,  a board-certified doctor in both emergency medicine and emergency medical...
02/22/2020
The Emotional and Psychological Struggle of Being a Doctor - Onco'Zine

In an OpEd in Onco'Zine, Shannon Sovndal, MD, a board-certified doctor in both emergency medicine and emergency medical services (EMS), and the author of Fragile: Beauty in Chaos, Grace in Tragedy, and the Hope that Lives In Between., writes about the emotional and psychological struggle of being a doctor.

https://www.oncozine.com/the-emotional-and-psychological-struggle-of-being-a-doctor/

#struggles #emotional #psychological #medicine #health #healthcare #cancer #ems #family #care #hospital #society #tragedy #emergency

The of Struggle of Being a Doctor: Shannon Sovndal, MD, author of Fragile: Beauty in Chaos, Grace in Tragedy, and the Hope that Lives In Between

Published in the Phoenix Business Journal
02/17/2020

Published in the Phoenix Business Journal

Catherine Ivy: A Tireless Advocate for Brain Cancer Patients
11/23/2019
Catherine Ivy: A Tireless Advocate for Brain Cancer Patients

Catherine Ivy: A Tireless Advocate for Brain Cancer Patients

In this edition of The Onco’Zine Brief Peter Hofland talks with Catherine Ivy, the Founder and President of the Ben & Catherine Ivy Foundation. The Ben & Catherine Ivy Foundation, established in 2005, is the largest non-government organization supporter of brain tumor - including glioblastoma (GBM...

ADC Directory, A Guide to the World of Antibody-drug Conjugates
10/02/2019

ADC Directory, A Guide to the World of Antibody-drug Conjugates

Design of Experiments (DoEs) are a specific application of statistical techniques to enable rapid and robust development. Those techniques can be directed towards factor screening or process robustness depending on the specific needs of the project phase. Often these experiments result in a stronger process understanding, while requiring less time and fewer material resources. Watch the Presentation On Demand.

https://adc.expert/NovasepDOE

Design of Experiments (DoEs) are a specific application of statistical techniques to enable rapid and robust development...
10/02/2019

Design of Experiments (DoEs) are a specific application of statistical techniques to enable rapid and robust development. Those techniques can be directed towards factor screening or process robustness depending on the specific needs of the project phase. Often these experiments result in a stronger process understanding, while requiring less time and fewer material resources. Watch the Presentation On Demand.

https://adc.expert/NovasepDOE

Become a Patreon of The Onco'Zine Brief - a weekly radio program / podcast show about cancer with expert interviews desi...
09/05/2019
Peter Hofland and the Onco'Zine Production Team are creating The Onco'Zine Brief (a public radio program & podcast) | Patreon

Become a Patreon of The Onco'Zine Brief - a weekly radio program / podcast show about cancer with expert interviews designed to educate and empower patients, learn from oncologists, hematologists, (oncology) nursing and allied healthcare professionals and share the latest updates with all stakeholders in the development of novel anti-cancer drugs.

http://bit.do/Support_The_Onco-Zine_Brief

Become a patron of Peter Hofland and the Onco'Zine Production Team today: Read 9 posts by Peter Hofland and the Onco'Zine Production Team and get access to exclusive content and experiences on the world’s largest membership platform for artists and creators.

In this edition of The Onco’Zine Brief Peter Hofland talks with Charlie Covert, Vice President & General Manager Targete...
05/06/2019
Ending the Opioid Crisis: How Targeted Drug Delivery May Improve Pain Management

In this edition of The Onco’Zine Brief Peter Hofland talks with Charlie Covert, Vice President & General Manager Targeted Drug Delivery, Restorative Therapies Group - Pain Division at Medtronic.

Hofland and Covert talk about opioids and pain management in patients with cancer. While considered safe, reliable, and effective for all types of pain, opioids are also a potentially abuseable drugs. And the public health consequence of opioid abuse is really bad.

More than 11.5 million people abused prescription opioids. As a result, every day, more than 1,000 people are treated in emergency departments for misusing prescription opioids.

The Centers for Disease Control and Prevention estimates the total economic burden of prescription opioid misuse in the United States alone, to be $78.5 billion dollar each year. This includes the costs of health care, lost productivity, addiction treatment, and the involvement of the criminal justice system.

A review of latest information also confirms that many steps to mitigate and reduce the risks associated with long-term systemic opioid use, including misuse, addiction and overdose -- have failed – leading to the Opioid Crisis we see today.

The burden of cancer continues to increase on a personal and societal level – and the National Cancer Institute projects that the yearly cost of cancer treatment in the United States will increase to $157 billion in 2020. And pain is prevalent in all cancer patients.

A recent study published in the journal of the American Medical Association confirms that 55 percent of cancer patients, undergoing active treatment, report pain.

Pain has been identified as a preventable reason for hospital admission and is associated with more than 40 percent of cancer Emergency Room visits. And despite increased health care utilization cost, in most cases, liberal oral opioid use for cancer pain, remains the standard of care.

So, what can be done to provide better care for patients? Are their alternatives?

In this episode Hofland and Covert talk about Medtronic, a company with a 40-year history of developing medical devices. One of Medtronic's options to help patients with acute and chronic pain involves Targeted Drug Delivery.

And the results of this approach are noteworthy.

In one study published in Neuromodulation, a peer-reviewed journal, patients report a reduction in pain scores after receiving targeted drug delivery. The journal also reports that more than 51% of patients completely eliminated the use of other prescribed opioids within 12 months.

Another study, this one published in the Journal of the American Medical Association, shows that using targeted drug delivery may also reduce health care utilization and cost for cancer-pain patients. This study found significant cost savings to payors, with fewer inpatient visits, shorter inpatient length of stay, and fewer emergency department visits.

This good news for doctors helping their patients.

It’s good news for friends and family members of cancer patients.

But above all, it’s good news for cancer patients suffering from acute and chronic pain.

In this edition of The Onco’Zine Brief Peter Hofland talks with Charlie Covert, Vice President & General Manager Targeted Drug Delivery, Restorative Therapies Group - Pain Division at Medtronic, about opioids and pain management in patients with cancer. While considered safe, reliable, and effecti...

In this edition of The Onco’Zine Brief Peter Hofland, PhD talks with Nader Sanai, MD, an internationally-recognized neur...
04/10/2019
A Bold Approach to Identify New and Effective Therapies for Malignant Brain Tumors

In this edition of The Onco’Zine Brief Peter Hofland, PhD talks with Nader Sanai, MD, an internationally-recognized neurosurgical oncologist with clinical and research expertise in the treatment of all brain tumors, including glioblastoma, the most aggressive cancer that begins within the brain. Sanai is the director of the Ivy Brain Tumor Center at the Barrow Neurological Institute in Phoenix, Arizona. He is also the principal architect of the Center’s accelerated clinical trials program, the largest in the word.

In this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Nader Sanai an internationally-recognized neurosurgical oncologist with clinical and research expertise in the treatment of all brain tumors, including glioblastoma, the most aggressive cancer that begins within the brain. Dr. San...

Grenzeloos Ondernemen
03/17/2019

Grenzeloos Ondernemen

Luister hier 👉 bit.ly/2TDCJc3 de #podcast van Grenzeloos Ondernemen in #Austin #Texas 🇺🇲️🎧. Vanuit New Dutch Wave/New Dutch Wave House op SXSW. Met Chantal Piët, van The Stroop Club. Mike Veldhuis van Nalta/Datumprikker.nl. Marleen Antelo-Van Helden van Smooth Summer Mobile Airbrush Tanning. En Sander van Meurs van YER.

Revolutionizing the Manufacturing of Antibody-Drug Conjugates - A Conversation with ADC Bio's Charlie Johnson | Peter Ho...
02/27/2019
Revolutionizing the Manufacturing of Antibody-Drug Conjugates - A Conversation with ADC Bio's Charlie Johnson | Peter Hofland on Patreon

Revolutionizing the Manufacturing of Antibody-Drug Conjugates - A Conversation with ADC Bio's Charlie Johnson | Peter Hofland on Patreon

Official Post from Peter Hofland: In this edition of The Onco’Zine Brief Peter Hofland talks with Charlie Johnson, Chief Executive Officer of ADC Bio, a biotechnology company, specialized in the development of Antibody-drug Conjugates.Antibody-drug Conjugates, also known as ADCs, are a novel type ...

Supreme Court Justice Ruth Bader Ginsburg has Malignant Lung Nodules Removed - Onco'Zine
12/23/2018
Supreme Court Justice Ruth Bader Ginsburg has Malignant Lung Nodules Removed - Onco'Zine

Supreme Court Justice Ruth Bader Ginsburg has Malignant Lung Nodules Removed - Onco'Zine

Today, Supreme Court Justice Ruth Bader Ginsburg, 85, underwent a lung procedure to remove malignant lung nodules. Doctors discovered the nodules during tests to treat rib fractures from a fall in November. It was not that long ago that it was rare to be diagnosed with lung cancer and live more than...

Two New Studies Explore Opioid Use in Cancer Care - Onco'Zine
09/25/2018
Two New Studies Explore Opioid Use in Cancer Care - Onco'Zine

Two New Studies Explore Opioid Use in Cancer Care - Onco'Zine

With nearly 16 million long-term cancer survivors, the treatment and care of patients with cancer has changed. But long-term cancer survivors may be plagued by chronic pain sequelae. To help these patients, researchers have identified the potential of strong opioid analgesics when they have advanced...

Onco'Zine - The International Cancer Network
09/23/2018
Onco'Zine - The International Cancer Network

Onco'Zine - The International Cancer Network

Just Published in OncoZine (the journal) - Eric Rosenthal Reports: "How a Hollywood-and-Scientist Dream Team Created a New Paradigm in Collaborative Cancer Research"

Address

4960 S Gilbert Rd, Ste 1286
Chandler, AZ
85249

General information

As a leading medical communication organization we're driven by our expertise in translating clinical data and complex scientific knowledge into motivating communication materials, communication services, and continuing medical education programs. Sunvalley Communication combines the strength and depth of its expertise to deliver medical information to physicians to meet the pre and post launch strategic, educational and marketing communications objectives of the bio/pharmaceutical and medical device industries via face to face meetings and exhibits, print and interactive technologies. Sunvalley Communication is an independent, specialist communications consultancy dedicated solely to the healthcare, pharmaceutical and medical device industries. The company’s mission is to exceed expectations, which is why so many of the world’s leading pharmaceutical companies trust us with their most important and valued products.

Opening Hours

Monday 09:00 - 18:00
Tuesday 09:00 - 18:00
Wednesday 09:00 - 18:00
Thursday 09:00 - 18:00
Friday 09:00 - 18:00

Telephone

(480) 626-7218

Alerts

Be the first to know and let us send you an email when Sunvalley Communication posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Videos

Nearby health & beauty businesses


Other Chandler health & beauty businesses

Show All